Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin

Naoyuki Kawahara, Toshiya Tanaka, Akira Yokomizo, Hiroki Nanri, Mayumi Ono, Morimasa Wada, Kimitoshi Kohno, Kenji Takenaka, Keizo Sugimachi, Michihiko Kuwano

Research output: Contribution to journalArticlepeer-review

108 Citations (Scopus)

Abstract

Thioredoxin (TRX), a disulfide-reducing intracellular protein, functions as a cellular defense mechanism against oxidative stress. In this study, we asked whether expression of TRX, glutathione-thiol transferase π, and high mobility group protein 1 (HMG-I) genes is enhanced in human hepatocellular carcinoma and whether expression of these genes is associated with sensitivity to cisplatin. Both TRX and HMG-1 were co-overexpressed in almost all cancerous lesions in comparison to normal tissue in surgically resected hepatocellular carcinomas of 20 patients. Tumor sensitivity to cisplatin [cis-diamminedichloroplatinum (II)], but not to mitomycin C or doxorubicin, correlated with mRNA levels of TRX in cancer tissue. TRX and HMG-1 may be useful tumor markers, and TRX might he also a useful marker for sensitivity to cisplatin in human hepatocellular carcinomas.

Original languageEnglish
Pages (from-to)5330-5333
Number of pages4
JournalCancer Research
Volume56
Issue number23
Publication statusPublished - Dec 1 1996

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin'. Together they form a unique fingerprint.

Cite this